Stock Track | Braveheart Bio Soars 67.78% in Debut After Upsized $383 Million IPO

Stock Track

Aug 07

Shares of Braveheart Bio Inc. (BRVE) soared 67.78% during intraday trading on Thursday, marking a stellar debut on the Nasdaq Global Market.

The surge comes after the clinical-stage biopharmaceutical company priced its upsized initial public offering at $18 per share, the high end of its marketing range. The company sold approximately 21.3 million shares, raising $382.5 million in gross proceeds, after increasing the deal size from 18.75 million shares and pricing above the initial $15 to $17 range. The strong investor demand for the offering fueled the significant first-day pop.

Braveheart Bio is focused on developing therapies for patients with hypertrophic cardiomyopathy and other serious cardiovascular diseases. The company intends to use the IPO proceeds to advance the development of its lead product candidate, BHB‑1893.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1150536472"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1150536472\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1150536472?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 00:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1150536472","market":"nz","top_or_hot":-1,"title":"Stock Track | Braveheart Bio Soars 67.78% in Debut After Upsized $383 Million IPO","media":"Stock Track","content":"<p>Shares of Braveheart Bio Inc. (BRVE) soared 67.78% during intraday trading on Thursday, marking a stellar debut on the Nasdaq Global Market.</p><p>The surge comes after the clinical-stage biopharmaceutical company priced its upsized initial public offering at $18 per share, the high end of its marketing range. The company sold approximately 21.3 million shares, raising $382.5 million in gross proceeds, after increasing the deal size from 18.75 million shares and pricing above the initial $15 to $17 range. The strong investor demand for the offering fueled the significant first-day pop.</p><p>Braveheart Bio is focused on developing therapies for patients with hypertrophic cardiomyopathy and other serious cardiovascular diseases. The company intends to use the IPO proceeds to advance the development of its lead product candidate, BHB‑1893.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Braveheart Bio Soars 67.78% in Debut After Upsized $383 Million IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Braveheart Bio Soars 67.78% in Debut After Upsized $383 Million IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-08-07 00:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Braveheart Bio Inc. (BRVE) soared 67.78% during intraday trading on Thursday, marking a stellar debut on the Nasdaq Global Market.</p><p>The surge comes after the clinical-stage biopharmaceutical company priced its upsized initial public offering at $18 per share, the high end of its marketing range. The company sold approximately 21.3 million shares, raising $382.5 million in gross proceeds, after increasing the deal size from 18.75 million shares and pricing above the initial $15 to $17 range. The strong investor demand for the offering fueled the significant first-day pop.</p><p>Braveheart Bio is focused on developing therapies for patients with hypertrophic cardiomyopathy and other serious cardiovascular diseases. The company intends to use the IPO proceeds to advance the development of its lead product candidate, BHB‑1893.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BRVE","symbol_name":"Braveheart Bio","start_time":0,"source_url":"","article_id":"1150536472","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1150536472","pubTimestamp":1786035174,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Braveheart Bio Inc. (BRVE) soared 67.78% during intraday trading on Thursday, marking a stellar debut on the Nasdaq Global Market.The surge comes after the clinical-stage biopharmaceutical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BRVE":"Braveheart Bio"},"translate_title":"股票追踪 | Braveheart Bio 首次公开募股规模扩大 3.83 亿美元后，首日股价飙升 67.78%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BRVE":1},"content_text":"Shares of Braveheart Bio Inc. (BRVE) soared 67.78% during intraday trading on Thursday, marking a stellar debut on the Nasdaq Global Market.The surge comes after the clinical-stage biopharmaceutical company priced its upsized initial public offering at $18 per share, the high end of its marketing range. The company sold approximately 21.3 million shares, raising $382.5 million in gross proceeds, after increasing the deal size from 18.75 million shares and pricing above the initial $15 to $17 range. The strong investor demand for the offering fueled the significant first-day pop.Braveheart Bio is focused on developing therapies for patients with hypertrophic cardiomyopathy and other serious cardiovascular diseases. The company intends to use the IPO proceeds to advance the development of its lead product candidate, BHB‑1893.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}